CBio bucks trend, achieves 'satisfactory' capital raising
17 July, 2002 by Pete YoungBrisbane biotech CBio is set to conclude an 11-month, $5 million capital raising that coincided with the worst investor environment in a decade.
Diabetes feature: the politics of diabetes
15 July, 2002 by Tanya HollisAs well as the many clinical research projects looking for cures and better treatments, a major emphasis in stemming the level of adult-onset diabetes in Australia lies in education and awareness.
Diabetes feature
15 July, 2002 by Tanya HollisAttend any major meeting on diabetes around the world and chances are there will be a fair contingent of Aussies in attendance. Australian researchers are renowned for their work in all facets of the disease, which experts say has now burgeoned to epidemic proportions.
Skin cancer prevention treatment developed at Uni of SA
11 July, 2002 by Melissa TrudingerScientists at the University of South Australia's Centre for Pharmaceutical Research have developed a topical treatment that could be used to prevent skin cancers from developing in susceptible people.
Prima meets cancer milestones
10 July, 2002 by Tanya HollisDrug development company Prima Biomed has told the market its first year research programs into cancer immunotherapy and anti-inflammatory treatments had met or exceeded their milestones.
Researchers welcome xenotransplantation guidelines
09 July, 2002 by Staff WritersAustralian researchers have welcomed the National Health and Medical Research Council's draft guidelines on xenotransplantation, released yesterday.
NHMRC gives cautious nod to xenotransplantation
08 July, 2002 by Iain ScottA working party of the National Health and Medical Research Council has offered its tentative approval of research involving the transplantation of cells from animals to humans.
Neurosciences Victoria signs three-year deal with Schering
04 July, 2002 by Melissa TrudingerNeurosciences Victoria (NSV) and Schering at the end of June announced that they had entered into a three year research collaboration focusing on drug discovery and target evaluation for neurodegenerative diseases.
Bacteria-SIDS connection identified
28 June, 2002 by Tanya HollisMonash University researchers have confirmed a link between bacterial infections and sudden infant death syndrome (SIDS).
Genesis begins trial for psoriasis treatment
28 June, 2002 by Melissa TrudingerGenesis Research and Development Corporation has commenced a Phase II clinical trial to test the efficacy of its PVAC treatment for psoriasis when administered in combination with Ultra Violet-B (UVB) light therapy.
Vision Systems buys UK biotech
27 June, 2002 by Tanya HollisVision Systems ASX: VSL) has surprised the market by buying a UK biochemical manufacturer outright.
Charity $22.5m kickstarts new Qld innovation institute
26 June, 2002 by Pete YoungThe latest gilt-edged donation to Queensland from a charity founded by US businessman Charles Feeney will kickstart construction on a $70 million Institute of Health and Biomedical Innovation.
Survey reveals how we think about being human
25 June, 2002 by Tanya HollisA survey of 7500 Australians on the issue of when an embryo is considered to be human has shown that most people do not believe a human is created at conception.
Meditech announces positive HyDOX results
07 June, 2002 by Melissa TrudingerMeditech Research has announced that its pre-clinical animal studies for anti-cancer drug HyDOX showed a three-fold reduction of heart damage.
IDT not concerned by AstraZeneca decision on cancer drug
07 June, 2002 by Tanya HollisPharmaceutical manufacturer Institute of Drug Technology may pursue direct talks with the UK developer of an early-stage anti-cancer drug after licensee AstraZeneca dumped the project.
